Navigation Links
Misonix Product Featured At Neurosurgery Congress

FARMINGDALE, N.Y., Aug. 28, 2012 /PRNewswire/ -- Misonix, Inc. (NasdaqGM: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, has announced its participation in the 43rd Annual Meeting of the Argentinian Association of Neurosurgery, which was held recently in Buenos Aires, Argentina. 

The Argentinian Association of Neurosurgery, with more than 500 members, is committed to physician education and to supporting research within its membership.  Close to 300 delegates attended the Annual Meeting.

In addition to exhibiting and demonstrating its BoneScalpel™ product platform, the Company benefited from a workshop on the use of the BoneScalpel in advanced spine surgery, which was conducted by a German guest speaker, Dr. Daniel Rosenthal, Director of Spine Surgery at the Bad Homburg Regional Hospital in Frankfurt, Germany. Among other comments, Dr. Rosenthal, who was born in Argentina, noted the precise nature of the bone cuts, minimal bone loss, reduced bleeding, reduction in procedure time and safety associated with the use of BoneScalpel.

To quote Dr. Rosenthal, "I use the BoneScalpel in arthrectomy or vertebrectomy, and to decompress the foramina.  In my opinion, it replaces the saw or drill in spine surgery."

In addition, two separate clinical poster sessions were presented by Dr. Juan P. Garraham, neurosurgeon at the National Children's Hospital, documenting his clinical success with BoneScalpel when used in deformity procedures such as scoliosis of the spine.

The BoneScalpel is a tissue specific osteotomy device capable of safely making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the danger associated with rotary sharps.  To date, reported uses of the Product in spine surgery include laminectomy, laminotomy, laminoplasty, corpectomy, spinal deformity, foraminotomy, facetectomy and other procedures performed by orthopedic and neuro surgeons.

"We were pleased to participate in this educational event that brings together practitioners and researchers from throughout Argentina and neighboring countries," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.  "Exhibiting our state-of-the-art technology at this prestigious gathering and having it supported by workshops and clinical support statements demonstrate our continuing commitment to providing products to the medical community that can provide meaningful benefits to patients."

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.Investor Relations ContactsMisonix Contact:

Lytham Partners, LLCRichard Zaremba

Robert Blum, Joe Dorame, Joe Diaz631-694-9555

SOURCE Misonix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Adds 6 Spine Sales Agencies In The U.S.
2. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
3. Misonix Inks New Distribution Agreement For Croatia And Slovenia
4. Misonix And Soelim Create New Distribution Alliance For South Korea
5. Misonix Participates In Cleveland Spine Review
6. Misonix Adds Industry Veteran To Management Team
7. Misonix Exhibits at Major Worldwide Spine Conference
8. Misonix And SIAD Healthcare Renew Distribution Agreement For Italy
9. Misonix Announces New Distribution Agreement For Panama
10. Report Highlights Key Activities that Drive Successful New Product Planning Groups in Pharmaceutical Industry
11. CLEANPATH RESOURCES CORP Announces Next Generation of Four Herbal Products
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, a ... treatment outcomes for patients suffering from chronic pain, said ... a Temporary Restraining Order (TRO) enjoining Express Scripts from ... companies. --> --> ... of its legal options. --> ...
(Date:11/25/2015)... USA , Inc., a leader in ... accuracy of its blood glucose meter systems. Last week ... Cardiovascular Disease in Los Angeles , ... 01 meter and the Assure ® Prism multi-user ... measure glucose levels in blood is essential for people ...
(Date:11/25/2015)... 25, 2015 Allergan plc (NYSE: AGN ) ... New York State Attorney General,s Office ... Act, and other statutes with the Attorney General over the ... cease marketing and selling the now generic version of memantine ... no liability, has released its counterclaims against New ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... and Cambridge, ON (PRWEB) , ... November 26, ... ... the availability of a real-time eReferral system for diagnostic imaging in the Waterloo ... X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical record ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... 2015 , ... PRMA Plastic Surgery is updating their record books yet again ... free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... and it’s an honor to have served all of these women.” , PRMA is ...
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
Breaking Medicine News(10 mins):